Xi' an Manareco New Materials Co. , Ltd. was established in 1999. It is jointly owned by investment institutions such as Zhuoshi Partnership and Gainful Investment, as well as senior management personnel within the company. The company is a high-tech enterprise focused on the research, development, production, and sales of specialized organic new materials. Its main products include monolithic liquid crystals, OLED materials, and innovative pharmaceutical intermediates. These materials are used in the production of OLED terminal materials, mixed liquid crystals, and active pharmaceutical ingredients. The company' s products find applications in OLED displays, TFT-LCD displays, and pharmaceutical formulations.
The company has established a“ One Headquarters, Multiple Bases” architectural system with its headquarters in Xi' an serving as the administrative and research and development center. The key components of this system include:Weinan Haitai as the main pilot production base; Pucheng Haitai as the ore production base; Ruilian Pharmaceutical as the API production base; Manareco Japan as the market development base for pharmaceutical business; Dali Ruilian and Dali Haitai as the capacity reserve bases. The company has a workforce of over 1700 full-time employees and provides a one-stop service that covers everything from small-scale research and development to pilot-scale amplification and industrial production. The company, located in the Xi' an High-tech Industries Development Zone, has a“ Provincial Enterprise Technology Center” that consists of 70 standard laboratories, over 200 sets of advanced testing equipment, and more than 400 research and development technicians. The company' s research and development investment has reached over 7%of its annual revenue. Currently, it possesses production technologies for more than 2800 compound varieties and holds 80 authorized patents. The production base has more than 40 production lines, which can carry out hundreds of chemical reactions such as acylation reaction, Grignard coupling reaction, Suzuki coupling reaction, hydrogenation reaction, Wittig reaction, hydrogen isotope substitution reaction, etc. With the support of the ERP system management platform, the implementation of 6S on-site management and SOP operating standard procedures, we are able to stably produce thousands of tons of products, meeting our customers' demands for industrialization.
Our company is one of the leading enterprises in the domestic OLED front-end materials industry. After years of close cooperation with global leading OLED terminal material manufacturers such as Idemitsu, Dupont, Merck, etc. , our company has become one of the few domestic enterprises that can achieve large-scale production of OLED materials. Our products have achieved full coverage of luminous layer materials and universal layer materials. Our company is a leading international enterprise in the research and development and production of monolithic liquid crystals. Our preparation technology for monolithic liquid crystals has reached the advanced level worldwide. We are the strategic supplier of the world-renowned companies Merck and JNC. With our experience and technical accumulation in cooperation with excellent enterprises, we have established long-term and stable cooperative relationships with major domestic mixed crystal manufacturers such as Bayi Space, Hecheng Display, and Slichem. Leveraging our rich technical experience in chemical synthesis, purification, trace analysis, and mass production systems in the field of display materials, we have extended our technology application to the pharmaceutical intermediate field. We have successfully developed pharmaceutical CMO/CDMO business. The first phase of the Ruilian Pharmaceutical API project workshop has been completed. Ruilian Pharmaceutical has obtained the“ Drug Production License” and is applying for GMP compliance inspection of relevant products, striving to establish an integrated CDMO industry chain of“ intermediates+APIs” .
In the future, our company will firmly implement a diversified development strategy focusing on two core main tracks:OLED materials and pharmaceutical CDMO business. We will continue to uphold the business philosophy of openness, integration, innovation, and development, insist on customer value creation as the orientation, actively explore new products, new customers, and new fields, and strive to become an international leading comprehensive and multi-level platform enterprise, providing healthy chemistry, green chemistry, and colorful chemistry for mankind.